WELLS FARGO & COMPANY/MN

Position in CAI — Caris Life Sciences, Inc.

CIK 72971 SAN FRANCISCO, CA

Back to CAI Full portfolio

Position in CAI

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$422,137

+$113,708 QoQ

Shares Held

23,689

+37.3% QoQ

Ownership

0.008%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#128

of 246 holders

Holding Since

Jun 2025

5 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in CAI Over Time

Shares Held

Position Value (USD)

Derivatives in CAI

reported options exposure · as of Dec 31, 2025

CallValue

$3,062,230

CallShares

113,500

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

WELLS FARGO & COMPANY/MN holds $1,567,775,044 across 417 Biotechnology names. CAI ranks #193 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	749,528	$372,313,040
2	HALO	Halozyme Therapeutics, Inc.	1,390,428	$108,828,797
3	ALNY	Alnylam Pharmaceuticals, Inc.	310,047	$93,333,446
4	REGN	Regeneron Pharmaceuticals, Inc.	140,802	$87,795,677
5	EXEL	Exelixis, Inc.	717,840	$39,057,673
6	RVMD	Revolution Medicines, Inc.	178,780	$33,481,916
7	ARGX	Argenx SE	34,453	$31,964,458
8	INCY	Incyte Corp	255,064	$28,914,053

All Filings in CAI

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$422,137	23,689	+37.3%	Shares	Defined	2026-08-14
2026-03-31	$308,429	17,250	+91.8%	Shares	Defined	2026-05-11
2025-12-31	$3,062,230	113,500	—	Call	Defined	2026-02-13
2025-12-31	$242,684	8,995	+408.2%	Shares	Defined	2026-02-13
2025-09-30	$53,542	1,770	+36.2%	Shares	Defined	2025-11-13
2025-06-30	$34,736	1,300	—	Shares	Defined	2025-08-14
No filing history on record for this holder in this stock.